AtriCure has announced that the first patient has been treated with the AtriClip FLEX-Mini left atrial appendage (LAA) exclusion device, which recently received US Food and Drug Administration (FDA) 510(k) clearance.
The company describes the AtriClip FLEX-Mini as the smallest profile surgical LAA device on the market, building on the technology of AtriCure’s AtriClip platform.
“The AtriClip FLEX-Mini is an unparalleled product that reinforces our position as the market leader in surgical LAA management,” said Michael Carrel, president and chief executive officer at AtriCure. “With nearly 600,000 AtriClip devices sold globally, we are having a significant impact on patients’ lives. Continuing to innovate and enhance the unique features of our AtriClip platform will support even greater growth in this market.”
“The AtriClip FLEX-Mini is a significant step forward in ensuring patients receive the best possible treatment,” said Ibrahim S Sultan (University of Pittsburgh Medical Center, Pittsburgh, USA). “This device builds off the first- and second-generation platforms, which established an incredible record of clinical outcomes. With surgical LAA management now having the highest-level recommendation for treatment from multiple physician societies, this new technology will make it even easier for my surgeon colleagues to choose mechanical appendage closure.”
